Patent intelligence · US
US 12396989
Nicorandil derivatives
Nicorandil derivatives
Patent details — US 12396989
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 26, 2025
- Expiration
- Aug 21, 2045
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Claims
- 15
- CPC classes
- A61K, A61K31/4425, A61K31/4545, A61K31/455
Quick answer
US 12396989 (Nicorandil derivatives) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Aug 26, 2025. Expires Aug 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/4425, A61K31/4545, A61K31/455, A61P, A61P13/12
More from UNICYCIVE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12396989?
US 12396989 (Nicorandil derivatives) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Aug 26, 2025. Expires Aug 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12396989?
UNICYCIVE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12396989 expire?
Our index shows an expiration date of Aug 21, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.